Balyasny Asset Management
SLS icon

Balyasny Asset Management’s SELLAS Life Sciences SLS Stock Holding History

Balyasny Asset Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-81,695
Closed -$564K – 3456
2026
Q1 		$346K Buy
+81,695
New +$365K ﹤0.01% 2510

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Balyasny Asset Management's SLS Position: Q2 2026 in Review

Balyasny Asset Management sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 81,695 shares — an estimated $564K sold.

Balyasny Asset Management first reported a position in SLS in Q1 2026 and held it in 1 quarter. The position peaked at $346K in Q1 2026. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Balyasny Asset Management reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 81,695 SELLAS Life Sciences shares in Q2 2026, an estimated $564K.
  • Balyasny Asset Management first reported a position in SELLAS Life Sciences in Q1 2026 and held it in 1 quarter.
  • Balyasny Asset Management's SELLAS Life Sciences position peaked at $346K in Q1 2026.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.